Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment - 13/11/21
, Juan Li a, Bin Tian a, Lei Tian a, b, Yuzhi Liu a, Jingyi Li a, Liang Xin a, Jun Wang a, c, Chao Fu d, Zhenfeng Shi e, Juan Xia f, Yiting Liang a, Kun Wang g, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 16 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifestation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead to liver cirrhosis. The pathological mechanism of NASH is multifactorial, involving a series of metabolic disorders and changes that trigger low-level inflammation in the liver and other organs. In the pathogenesis of NASH, the signal transduction pathway involving succinate and the succinate receptor (G-protein-coupled receptor 91, GPR91) regulates inflammatory cell activation and liver fibrosis. This review describes the mechanism of the succinate–GPR91 signalling pathway in NASH and summarizes the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The key mechanism of NASH pathogenesis is fully elucidated. |
• | The emerging succinate–GPR91 signalling pathway of NASH progression is described. |
• | The succinate–GPR91 signalling pathway is related to liver inflammation and fibrosis. |
• | NASH candidates that could act on the succinate–GPR91 signalling pathway are identified. |
• | Targeting upstream and midstream of succinate–GPR91 may be more effective for NASH. |
Abbreviations : Akt, ALT, AMPK, AST, DHA, ERK, FGF21, FXR, GPR91, HFCD-HF/G, HSCs, IL-1β, LX2 cells, MCD, NAFL, NAFLD, NAS, NASH, NF-κB, PEG, PI3K, SDH, SIRT3, T2DM, TCA, TF, TGF-β, TNF-α, WAT, α-SMA
Keywords : Non-alcoholic steatohepatitis (NASH), Non-alcoholic fatty liver disease (NAFLD), Succinate–GPR91, Liver fibrosis, Hepatic stellate cells (HSCs)
Plan
Vol 144
Article 112298- décembre 2021 Retour au numéro
Article précédent
- Targeting miRNAs with anesthetics in cancer: Current understanding and future perspectives
- Peyman Tabnak, Soroush Masrouri, Kiarash Roustai Geraylow, Mahtab Zarei, Zanyar Haji Esmailpoor
- The role of natural antioxidants in cisplatin-induced hepatotoxicity
- Norhashima Abd Rashid, Syarifah Aisyah Syed Abd Halim, Seong Lin Teoh, Siti Balkis Budin, Farida Hussan, Nurul Raudzah Adib Ridzuan, Nahdia Afiifah Abdul Jalil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?